Reduction in seizure burden in a child with a A350V IQSEC2 mutation using heat therapy with a Jacuzzi

Andrew P Levy | Nina S Levy | Eli Heyman | Mitchell Schertz | Jacob Genizi

CASE REPORT

Reduction in seizure burden in a child with a A350V IQSEC2 mutation using heat therapy with a Jacuzzi

Andrew P Levy | Nina S Levy | Eli Heyman | Mitchell Schertz | Jacob Genizi

INTRODUCTION

A350V IQSEC2 mutation and features of its associated seizures prompting this case report

Mutations in the X-linked human IQSEC2 gene (NM_001111125; MIM 300522) are associated with epilepsy as well as severe disturbances in cognitive and social behavioral functioning. Seizures in male children with IQSEC2 mutations are drug resistant in over 80% of cases. Over the past several years, we have studied the pathophysiology and clinical course of one specific human IQSEC2 missense mutation (A350V defined as a valine for alanine substitution at amino acid residue number 350 of the IQSEC2 protein).

Over 20 different seizure medications and a ketogenic diet have failed to reduce seizures in the male child E.H. hemizygous for the A350V IQSEC2 mutation. The failure of conventional medical treatment to suppress the child’s seizures has prompted our group to investigate alternative approaches. A remarkable finding in this child repeatedly observed by his parents beginning at 1 year of age until the present (age 8) is that when he has a fever of greater than 38°C lasting more than 1 day his seizures abruptly stop and then he has a seizure-free window of up to 3 weeks

Abstract

A child with a A350V IQSEC2 missense mutation resulting in drug-resistant epilepsy stops having seizures when he has a fever. We demonstrate that raising the body temperature of the child using a commercial Jacuzzi dramatically reduces his seizures and appears to improve his social behavioral interactions.

KEYWORDS

child development, epilepsy, heat shock, IQSEC2, thermal therapy

1 | INTRODUCTION

1.1 A350V IQSEC2 mutation and features of its associated seizures prompting this case report

Mutations in the X-linked human IQSEC2 gene (NM_001111125; MIM 300522) are associated with epilepsy as well as severe disturbances in cognitive and social behavioral functioning. Seizures in male children with IQSEC2 mutations are drug resistant in over 80% of cases. Over the past several years, we have studied the pathophysiology and clinical course of one specific human IQSEC2 missense mutation (A350V defined as a valine for alanine substitution at amino acid residue number 350 of the IQSEC2 protein).

Over 20 different seizure medications and a ketogenic diet have failed to reduce seizures in the male child E.H. hemizygous for the A350V IQSEC2 mutation. The failure of conventional medical treatment to suppress the child’s seizures has prompted our group to investigate alternative approaches. A remarkable finding in this child repeatedly observed by his parents beginning at 1 year of age until the present (age 8) is that when he has a fever of greater than 38°C lasting more than 1 day his seizures abruptly stop and then he has a seizure-free window of up to 3 weeks
after the fever has resolved. In this case report, we set out to determine whether the purposeful induction of a rise in body core temperature could have the same benefit as fever on reducing seizures.

2 | CASE REPORT

We have previously reported on the developmental progression of EH thru age 5 including the onset of seizures at age 8 months and the refractory nature of these seizures to all treatments.\(^5\) Seizure activity has been repeatedly documented using video EEG with the most recent EEG prior to this study (12/2019) showing nearly continuous severe epileptiform activity which was well correlated with frequent short head drops as well as generalized tonic-clonic (GTC) seizures and drop attacks. Prior to beginning this current investigation, the frequency of different seizure types was very variable from day to day, but it was not uncommon for the child to have over 20 seizures a day and due to post-ictal effects to be lethargic and non-interactive a substantial portion of the day.

We considered several possibilities to try to raise the child’s body core temperature to see if we could recapitulate the apparent protective effect of fever on seizures as described above. Previous studies have established that 15- to 20-min exposures to water baths at 40°C can safely raise the body core temperature to up to 39°C without risk of hyperthermia.\(^7\)\(^-\)\(^9\) We chose for this purpose a temperature-controlled water bath (Coleman 13804-BW SaluSpa), which is sold commercially as a Jacuzzi and operated the Jacuzzi at a setting of 40°C. The child was encouraged to sit in the Jacuzzi for treatments of up to 20 min and was monitored closely by an adult caregiver. More often the child would jump around and play during these treatments.

Beginning in October 2020, 2 months prior to initiating the Jacuzzi treatments the child’s seizures were carefully documented for 2–3 h a day by a single caretaker and recorded as being either small (head drops) or large (tonic-clonic followed by post-ictal drowsiness lasting at least 15 min). Once daily outdoor Jacuzzi treatments without any control of the air temperature of the region surrounding the Jacuzzi (temperature outside the Jacuzzi ranging from 10 to 15°C) were initiated in December 2020 with no apparent benefit on the number of head drops or GTC seizures. Beginning in February 2021, twice daily Jacuzzi treatments were initiated in conjunction with the housing of the Jacuzzi inside a tent and the installation of a heating system in the tent allowing the air temperature in the tent to be controlled at 30°C during the Jacuzzi treatments. Figure 1 demonstrates the percentage of days per 30-day interval that the child was observed to have at least two observed head drops or one GTC seizure over the four consecutive 30-day intervals prior to beginning the twice daily Jacuzzi treatments and during the 30-day period when he received twice daily treatments (average of 7–11 days per 30-day interval prior to twice daily treatments compared to 1 day during the 30-day interval of twice daily treatments, \(p = 0.003\) calculated by the chi-square test comparing the frequency of days with seizures for the 4 months before and the 30-day interval on twice daily Jacuzzi treatments).

**FIGURE 1** Seizure burden before and after twice daily Jacuzzi treatments. Histogram showing the percentage of days per 30-day interval in which EH was observed to have at least two head drops or one GTC seizure. Documentation of seizures was initiated October 10, 2019. Once daily Jacuzzi treatments without control of air temperature were initiated in the beginning of December 2020, and twice daily treatments with maintenance of air temperature at 30°C were initiated on February 10, 2021. Time periods in histogram are given as: period A-October 10, 2019- November 10, 2019; period B-November 11, 2019- December 10, 2019; period C-December 11, 2019-January 10, 2020; period D- January 11, 2021-February 10, 2021; period E-February 11, 2021 to March 10, 2021. (***\(p = 0.003\) calculated by chi-square test for frequency of days with seizures prior and after twice daily Jacuzzi treatments)
FIGURE 2 Differences in epileptiform and baseline brain wave activity seen on EEG before (Dec 2019) and after (March 2021) twice daily Jacuzzi treatments. There was a marked reduction in interictal discharges seen after initiating Jacuzzi treatments (6 per minute before treatment as shown in A1, compared to 1 per minute after treatment as shown in A2). The distribution of brain wave activity showed prominent delta wave activity prior to treatment (B1) compared to normal sleep patterns after treatment (B2). (A1) Interictal EEG discharges before Jacuzzi treatment. (A2) Interictal EEG discharges after Jacuzzi treatment. (B1) Background EEG activity before Jacuzzi treatment showing delta waves. (B2) Background EEG activity after Jacuzzi treatment showing normal sleep patterns.
During the 30-day interval, in which the child received twice daily Jacuzzi treatments, the child was more alert and interactive with his caregivers and teachers. His sleep was also markedly improved. Although the child is averbal, during this period the child demonstrated increased vocalizations.

After 30 days of twice daily Jacuzzi treatments, an EEG was performed (March 2021) and demonstrated a marked improvement in the amount of epileptiform activity. Representative EEGs from the period before and after the twice daily Jacuzzi treatments are shown in Figure 2. Interictal discharges were manually counted over a representative 20-min interval of the pre-treatment and on-treatment EEGs. Compared to his most recent EEG done prior to the Jacuzzi treatments (Dec 2019) there was a marked reduction in interictal discharges (A1 prior and A2 after treatment; mean of six interictal discharges per minute compared to one interictal discharge per minute). Moreover, background brain wave activity of the EEG after treatment was markedly improved (B1 prior and B2 after treatment) with normal sleep patterns after twice daily Jacuzzi treatments and a reduction in delta wave activity seen prior to treatment.

3 | DISCUSSION AND OUTLOOK

In this case report, we have observed objective benefit of frequent treatments in a 40°C Jacuzzi on seizure burden in a child with intractable epilepsy. This may be mediated by a similar biological process as seen in the child when he has had a fever in the past and had stopped having seizures. We are currently investigating the mechanism for this apparent relationship between body core temperature and seizures with the A350V IQSEC2 mutation in preclinical models using patient-derived stem cells and in a CRISPR generated mouse model of the A350V IQSEC2 mutation. We have proposed that the protection by elevated temperature may be mediated by the induction of specific heat shock proteins which can act as molecular chaperones aiding in the refolding of denatured or misfolded (as from a missense mutation) proteins. In general, such chaperones recognize newly exposed hydrophobic domains of proteins with the alanine to valine amino acid substitution in A350V possibly providing such an epitope. It is not clear whether children with different IQSEC2 mutations might be helped with this treatment. We hope that the reduction in seizure burden which this treatment appears to provide to a child with the A350V IQSEC2 mutation may permit for at least a partial improvement in his neurodevelopmental progression. Furthermore, as improvement in symptoms of autism by fever has been seen in many children, the significance of the current report may potentially extend beyond the single case of an A350V IQSEC2 mutation examined here.

ACKNOWLEDGEMENTS

We would like to thank David Lieberman and Michael Arnold for providing the Jacuzzi as a gift.

CONFLICT OF INTEREST

None declared.

AUTHOR CONTRIBUTIONS

APL: designed the study, wrote the case report; NSL: helped with writing the case report; EH: obtained EEG, helped to review manuscript; MS: helped to write the case report; JG: helped to write the case report, obtained EEG and performed comparative analysis of EEG pre and post treatment.

APPROVAL AND CONSENT

The parents of EH provided informed consent for his Jacuzzi treatments and to use the data from his seizures in this case report.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Andrew P Levy https://orcid.org/0000-0003-0195-5178

REFERENCES

1. Shoubridge C, Tarpey PS, Abidi F, et al. Mutations in the guanine nucleotide exchange factor gene IQSEC2 cause nonsyndromic intellectual disability. Nat Genet. 2010;42:486-488.
2. Zerem A, Haginoya K, Lev D, et al. The molecular and phenotypic spectrum of IQSEC2-related epilepsy. Epilepsia. 2016;57:1858-1869.
3. Shoubridge C, Harvey RJ, Dudding-Byth T. IQSEC2 mutation update and review of the female-specific phenotype spectrum including intellectual disability and epilepsy. Hum Mutat. 2019;40:5-24.
4. Mignot C, Depienne C. IQSEC2 related encephalopathy in males and females: a comparative study including 37 novel patients. Genet Med. 2019;21:837-849.
5. Zipper R, Baine SD, Genizi J, Maoz H, Levy NS, Levy AP. Developmental progression of intellectual disability, autism and epilepsy in a child with an IQSEC2 gene mutation. Clin Case Rep. 2017;5:1639-1643.
6. Rogers EJ, Jada R, Schagenheim-Rozales K, et al. An IQSEC2 mutation associated with intellectual disability and autism results in decreased surface AMPA receptors. Front Mol Neuroscience. 2019;12:43.
7. Faulkner SH, Jackson S, Fatania G, Leicht CA. The effect of passive heating on heat shock protein 70 and interleukin-6: a
possible treatment tool for metabolic diseases? Temperature. 2017;4:292-304.

8. Allison TG, Reger WE. Comparison of responses of men to immersion in circulating water at 40.0 and 41.5 degrees C. Aviat Space Environ Med. 1998;69:845-850.

9. Miwa C, Matsukawa T, Iwase S, et al. Human cardiovascular responses to a 60-min bath at 40 degrees C. Environ Med. 1994;38:77-80.

10. Hunt AP, Minett GM, Gibson OR, Kerr GK, Stewart IB. Could heat therapy be an effective treatment for Alzheimer’s and Parkinson’s disease? a narrative review. Front Physiology. 2020;10:1556.

11. Paul S, Mahanta S. Association of heat shock proteins in various neurodegenerative disorders: is it a master key to open the therapeutic door? Mol Cell Biochem. 2014;386:45-61.

12. Hasday JD, Singh IS. Fever and heat shock response: distinct, partially overlapping processes. Cell Stress Chaperones. 2000;5:471-480.

13. Duveau V, Arthand S, Serre H, Rougier A, La Salle GLG. Transient hyperthermia protects against subsequent seizures and epilepsy induced cell damage in the rat. Neurobio Dis. 2005;19:142-149.

14. Karunanithi S, Brown IR. Heat shock response and homeostatic plasticity. Front Cell Neuro. 2015;9:68.

15. Luengo TM, Mayer MP, Rudiger SGD. The HSP 70-Hsp 90 chaperone cascade in protein folding. Trends Cell Biol. 2019;29:164.

16. Karras GI, Yi S, Sahni N, et al. HSP 90 shapes the consequences of human genetic variation. Cell. 2017;168:856-866.

17. Curran LK, Newschaffer CJ, Lee LC, Crawford SO, Johnston MV, Zimmerman AW. Behaviors associated with fever in children with autism spectrum disorders. Pediatrics. 2007;120:e1386-e1392. https://doi.org/10.1542/peds.2007-03600

18. Grzadzinski R, Lord C, Sanders SI, Werling D, Bal VH. Children with autism spectrum disorder who improve with fever: insights from the simons simplex collection. Autism Res. 2018;11:175-184.

How to cite this article: Levy AP, Levy NS, Heyman E, Schertz M, Genizi J. Reduction in seizure burden in a child with a A350V IQSEC2 mutation using heat therapy with a Jacuzzi. Clin Case Rep. 2021;00:e04734. https://doi.org/10.1002/ccr3.4734